158 related articles for article (PubMed ID: 24081804)
1. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas.
Kruijff S; Sidhu SB; Sywak MS; Gill AJ; Delbridge LW
Ann Surg Oncol; 2014 Feb; 21(2):426-33. PubMed ID: 24081804
[TBL] [Abstract][Full Text] [Related]
2. Molecular Characteristics of Large Parathyroid Adenomas.
Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
[TBL] [Abstract][Full Text] [Related]
3. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
[TBL] [Abstract][Full Text] [Related]
4. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
[TBL] [Abstract][Full Text] [Related]
5. Defining a molecular phenotype for benign and malignant parathyroid tumors.
Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
[TBL] [Abstract][Full Text] [Related]
7. High index of clinical suspicion with optimal surgical techniques and adjuvant radiotherapy is critical to reduce locoregional disease progression in parathyroid carcinoma.
Selvan B; Paul MJ; Seshadri MS; Thomas N; Paul T; Abraham D; Oommen R; Shandhly N; John S; Rajaratnam S; Therese MM; Nair A; Kumar Samuel P
Am J Clin Oncol; 2013 Feb; 36(1):64-9. PubMed ID: 22270105
[TBL] [Abstract][Full Text] [Related]
8. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
[TBL] [Abstract][Full Text] [Related]
10. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
Juhlin CC; Nilsson IL; Lagerstedt-Robinson K; Stenman A; Bränström R; Tham E; Höög A
Mod Pathol; 2019 Jul; 32(8):1082-1094. PubMed ID: 30923346
[TBL] [Abstract][Full Text] [Related]
11. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
[TBL] [Abstract][Full Text] [Related]
12. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
Juhlin CC; Nilsson IL; Johansson K; Haglund F; Villablanca A; Höög A; Larsson C
Endocr Pathol; 2010 Sep; 21(3):166-77. PubMed ID: 20473645
[TBL] [Abstract][Full Text] [Related]
13. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
[TBL] [Abstract][Full Text] [Related]
14. Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms.
Kumari N; Chaudhary N; Pradhan R; Agarwal A; Krishnani N
Endocr Pathol; 2016 Jun; 27(2):87-96. PubMed ID: 26984237
[TBL] [Abstract][Full Text] [Related]
15. Classification of parathyroid cancer.
Schulte KM; Gill AJ; Barczynski M; Karakas E; Miyauchi A; Knoefel WT; Lombardi CP; Talat N; Diaz-Cano S; Grant CS
Ann Surg Oncol; 2012 Aug; 19(8):2620-8. PubMed ID: 22434247
[TBL] [Abstract][Full Text] [Related]
16. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
[TBL] [Abstract][Full Text] [Related]
17. Functional parathyroid carcinoma: Long-term treatment outcome and risk factor analysis.
Iihara M; Okamoto T; Suzuki R; Kawamata A; Nishikawa T; Kobayashi M; Obara T
Surgery; 2007 Dec; 142(6):936-43; discussion 943.e1. PubMed ID: 18063079
[TBL] [Abstract][Full Text] [Related]
18. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.
Vargas MP; Vargas HI; Kleiner DE; Merino MJ
Mod Pathol; 1997 Jan; 10(1):12-7. PubMed ID: 9021722
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis.
Stojadinovic A; Hoos A; Nissan A; Dudas ME; Cordon-Cardo C; Shaha AR; Brennan MF; Singh B; Ghossein RA
Hum Pathol; 2003 Jan; 34(1):54-64. PubMed ID: 12605367
[TBL] [Abstract][Full Text] [Related]
20. A nationwide study on parathyroid carcinoma.
Ryhänen EM; Leijon H; Metso S; Eloranta E; Korsoff P; Ahtiainen P; Kekäläinen P; Tamminen M; Ristamäki R; Knutar O; Löyttyniemi E; Niskanen L; Väisänen M; Heiskanen I; Välimäki MJ; Laakso M; Haglund C; Arola J; Schalin-Jäntti C
Acta Oncol; 2017 Jul; 56(7):991-1003. PubMed ID: 28362521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
